Acta Microbiologica et Immunologica Hungarica
Volume/Issue:
Volume 70: Issue 2
Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains
Authors:
Rıza Adaleti University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Laboratory of Medical Microbiology, Istanbul, Türkiye

Search for other papers by Rıza Adaleti in
Current site
Google Scholar
PubMed Close
https://orcid.org/0000-0001-9576-6794
,
Yaşar Nakipoğlu Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, 34093, Capa/Istanbul, Türkiye

Search for other papers by Yaşar Nakipoğlu in
Current site
Google Scholar
PubMed Close
,
Şeyma Çalık Ministry of Health, Directorate of Public Health, Amasya, Türkiye

Search for other papers by Şeyma Çalık in
Current site
Google Scholar
PubMed Close
,
Neslihan Arıcı University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Laboratory of Medical Microbiology, Istanbul, Türkiye

Search for other papers by Neslihan Arıcı in
Current site
Google Scholar
PubMed Close
,
Nilgün Kansak University of Health Sciences, Haydarpaşa Numune Training and Research Hospital, Laboratory of Medical Microbiology, Istanbul, Türkiye

Search for other papers by Nilgün Kansak in
Current site
Google Scholar
PubMed Close
,
Seniha Şenbayrak Department of Infectious Diseases and Clinical Microbiology, Hamidiye Medical Faculty, University of Health Sciences, Istanbul, Türkiye

Search for other papers by Seniha Şenbayrak in
Current site
Google Scholar
PubMed Close
, and
Sebahat Aksaray Department of Medical Microbiology, Hamidiye Medical Faculty, University of Health Sciences, Istanbul, Türkiye

Search for other papers by Sebahat Aksaray in
Current site
Google Scholar
PubMed Close
Pages:
155–160
Online Publication Date:
02 May 2023
Publication Date:
16 Jun 2023
Article Category:
Research Article
DOI:
https://doi.org/10.1556/030.2023.02015
Keywords:
antibiotic combination; fosfomycin; in vitro; Klebsiella pneumoniae; meropenem; polymyxin B
Restricted access

Abstract

The incidence of infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) is increasing worldwide, and very limited number of effective antibiotics are available for therapy. In our study, the in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against CRKP strains was investigated. The efficiency of meropenem/polymyxin B and meropenem/fosfomycin combinations was tested by checkerboard microdilution and checkerboard agar dilution methods, respectively, against 21 CRKP strains containing major carbapenem resistant genes (7 blaKPC, 7 blaOXA-48 gene, and 7 blaOXA-48+ blaNDM), and seven additional CRKP strains without carbapenemase genes.

Among the 28 CRKP strains, the meropenem/polymyxin B combination was synergistic in ten (35.7%), partially synergistic in 12 (42.8%), and indifferent in six (21.4%) isolates. The meropenem/fosfomycin combination was found to be synergistic in three isolates (10.7%), partially synergistic in 20 (71.4%), and indifferent in five (17.8%). In 21 strains containing carbapenem resistance genes, meropenem/polymyxin B and meropenem/fosfomycin combinations exhibited synergistic/partial synergistic effects in 15 (71.4%) and 16 (76.2%) strains, respectively, compared to 100% synergistic/partial synergistic efficiency in both combinations in seven strains free of carbapenemase genes. No antagonistic effect was detected in either combination.

Regardless of presence or absence of carbapenem resistance genes, meropenem/polymyxin B and meropenem/fosfomycin combinations both demonstrated high synergistic and partial synergistic activity against 78.4% and 82.1% of CRKP strains, respectively. Also, they have no antagonistic effects and can be used successfully to prevent therapeutic failure with monotherapy, according to our in vitro studies.

  • 1.

    Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob 2017; 29, 16(1):18: 1–12. https://doi.org/10.1186/s12941-017-0191-3.

    • Search Google Scholar
    • Export Citation
  • 2.

    Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect 2019; 25(8): 943–950. https://doi.org/10.1016/j.cmi.2019.04.013.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections in children. J Pediatr Infect Dis Soc 2020; 28; 9(1): 56–66. Available from: https://doi.org/10.1093/jpids/piz085.

    • Search Google Scholar
    • Export Citation
  • 4.

    Çalık Ş, Kansak N, Aksaray S. Phenotypic detection of carbapenemase production in carbapenem-resistant isolates with the rapid carbapenemase detection method (rCDM). J Microbiol Methods 2022; 200: 1–7. https://doi.org/10.1016/j.mimet.2022.106536.

    • Search Google Scholar
    • Export Citation
  • 5.

    The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. http://www.eucast.org.

    • Search Google Scholar
    • Export Citation
  • 6.

    JA Hindler and RM Humphrie. Antimicrobial susceptibility testing, pp: 813–1110: Amy L L.clinical microbiology procedures hand book. 2016 4th ed. ASM Press. Washington D C.

    • Search Google Scholar
    • Export Citation
  • 7.

    Firmo EF, Oliveira Júnior JB, Scavuzzi AML, Alves LC, Brayner FA, Veras DL, et al. In vitro activity of polymyxin B in combination with meropenem, amikacin and gentamicin against Klebsiella pneumoniae clinical isolates co-harbouring aminoglycoside-modifying enzymes, blaNDM-1 and blaKPC-2. J Glob Antimicrob Resist 2020; 22: 511–514. https://doi.org/10.1016/j.jgar.2020.04.014.

    • Search Google Scholar
    • Export Citation
  • 8.

    Sharma R, Patel S, Abboud C, Diep J, Ly NS, Pogue JM, et al. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. Int J Antimicrob Agents 2017; 49(2): 224–232. https://doi.org/10.1016/j.ijantimicag.2016.10.025.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Souli M, Galani I, Boukovalas S, Gourgoulis MG, Chryssouli Z, Kanellakopoulou K, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55(5): 2395–2397. https://doi.org/10.1128/AAC.01086-10.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58(4): 2322–2328. https://doi.org/10.1128/AAC.02166-13.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48(1): 15–22. https://doi.org/10.1128/AAC.48.1.15-22.2004.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Süzük Yıldız S, Şimşek H, Bakkaloğlu Z, Numanoğlu Çevik Y, Hekimoğlu CH, Kılıç S, et al.Ulusal Karbapenemaz Sürveyans ÇalışmaGrubu. Türkiye’de 2019. Yılı İçinde İzole edilen Escherichia coli ve Klebsiella pneumoniae İzolatlarında Karbapenemaz epidemiyolojisi [The epidemiology of carbapenemases in Escherichia coli and Klebsiella pneumoniae isolated in 2019 in Turkey]. Mikrobiyol Bul 2021 Jan; 55(1): 1–16. Turkİsh. https://doi.org/10.5578/mb.20124.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Bassetti M, Giacobbe DR, Giamarellou H, Viscoli C, Daikos GL, Dimopoulos G, et al. Critically Ill patients study group of the European society of clinical microbiology and infectious disease (ESCMID); Hellenic society of chemotherapy (HSC) and Società Italiana di Terapia anti infettiva (SITA). Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect 2018; 24(2): 133–144. https://doi.org/10.1016/j.cmi.2017.08.030.

    • Search Google Scholar
    • Export Citation
  • 14.

    Evren E, Azap OK, Çolakoğlu Ş, Arslan H. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 2013; 76(3): 335–338. https://doi.org/10.1016/j.diagmicrobio.2013.04.004.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Erturk Sengel B, Altinkanat Gelmez G, Soyletir G, Korten V. In vitro synergistic activity of Fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae. J Chemother 2020; 32(5): 237–243 https://doi.org/10.1080/1120009X.2020.1745501.

    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand
Cover Acta Microbiologica et Immunologica Hungarica
Acta Microbiologica et Immunologica Hungarica A Quarterly of the Hungarian Academy of Sciences
Print ISSN:
1217-8950
Online ISSN:
1588-2640

Senior editors

Editor-in-Chief: Prof. Dóra Szabó (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Managing Editor: Dr. Béla Kocsis (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Co-editor: Dr. Andrea Horváth (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)

Editorial Board

  • Prof. Éva ÁDÁM (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Sebastian AMYES (Department of Medical Microbiology, University of Edinburgh, Edinburgh, UK.)
  • Dr. Katalin BURIÁN (Institute of Clinical Microbiology University of Szeged, Szeged, Hungary; Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary.)
  • Dr. Orsolya DOBAY (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Ildikó Rita DUNAY (Institute of Inflammation and Neurodegeneration, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany; Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany)
  • Prof. Levente EMŐDY(Department of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary.)
  • Prof. Anna ERDEI (Department of Immunology, Eötvös Loránd University, Budapest, Hungary, MTA-ELTE Immunology Research Group, Eötvös Loránd University, Budapest, Hungary.)
  • Prof. Éva Mária FENYŐ (Division of Medical Microbiology, University of Lund, Lund, Sweden)
  • Prof. László FODOR (Department of Microbiology and Infectious Diseases, University of Veterinary Medicine, Budapest, Hungary)
  • Prof. József KÓNYA (Department of Medical Microbiology, University of Debrecen, Debrecen, Hungary)
  • Prof. Yvette MÁNDI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Károly MÁRIALIGETI (Department of Microbiology, Eötvös Loránd University, Budapest, Hungary)
  • Prof. János MINÁROVITS (Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged, Hungary)
  • Prof. Béla NAGY (Centre for Agricultural Research, Institute for Veterinary Medical Research, Budapest, Hungary.)
  • Prof. István NÁSZ (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Kristóf NÉKÁM (Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary.)
  • Dr. Eszter OSTORHÁZI (Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary)
  • Prof. Rozália PUSZTAI (Department of Medical Microbiology and Immunobiology, University of Szeged, Szeged, Hungary)
  • Prof. Peter L. RÁDY (Department of Dermatology, University of Texas, Houston, Texas, USA)
  • Prof. Éva RAJNAVÖLGYI (Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary)
  • Prof. Ferenc ROZGONYI (Institute of Laboratory Medicine, Semmelweis University, Budapest, Hungary)
  • Prof. Joseph G. SINKOVICS (The Cancer Institute, St. Joseph’s Hospital, Tampa, Florida, USA)
  • Prof. Júlia SZEKERES (Department of Medical Biology, University of Pécs, Pécs, Hungary.)
  • Prof. Mária TAKÁCS (National Reference Laboratory for Viral Zoonoses, National Public Health Center, Budapest, Hungary.)
  • Prof. Edit URBÁN (Department of Medical Microbiology and Immunology University of Pécs, Pécs, Hungary; Institute of Translational Medicine, University of Pécs, Pécs, Hungary.)

 

Editorial Office:
Akadémiai Kiadó Zrt.
Budafoki út 187-187, A/3, H-1117 Budapest, Hungary

Editorial Correspondence:
Acta Microbiologica et Immunologica Hungarica
Institute of Medical Microbiology
Semmelweis University
P.O. Box 370
H-1445 Budapest, Hungary
Phone: + 36 1 459 1500 ext. 56101
Fax: (36 1) 210 2959
E-mail: amih@med.semmelweis-univ.hu

 Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • CABELLS Journalytics
  • Chemical Abstracts
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Science Citation Index Expanded

2024  
Scopus  
CiteScore  
CiteScore rank  
SNIP  
Scimago  
SJR index 0.41
SJR Q rank Q3

2023  
Web of Science  
Journal Impact Factor 1.3
Rank by Impact Factor Q4 (Immunology)
Journal Citation Indicator 0.31
Scopus  
CiteScore 2.3
CiteScore rank Q3 (Infectious Diseases)
SNIP 0.389
Scimago  
SJR index 0.308
SJR Q rank Q3

Acta Microbiologica et Immunologica Hungarica
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article (only for OA publications)
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 772 EUR / 848 USD
Print + online subscription: 860 EUR / 944 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Acta Microbiologica et Immunologica Hungarica
Language English
Size A4
Year of
Foundation		 1954
Volumes
per Year		 1
Issues
per Year		 4
Founder Magyar Tudományos Akadémia
Founder's
Address		 H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 1217-8950 (Print)
ISSN 1588-2640 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Dec 2024 67 0 0
Jan 2025 52 0 0
Feb 2025 85 0 0
Mar 2025 76 0 0
Apr 2025 51 5 4
May 2025 56 1 0
Jun 2025 34 0 0